MedTrace Logo

A Prospective Multi-center Study on Using Sonazoid Diagnose Early Stage Endometrial Cancer

NCT04961775 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 277

Last updated 2021-07-14

No results posted yet for this study

Summary

Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of Sonazoid specific angiography and higher mechanical index, the role of Sonazoid in the early diagnosis of Endometrial carcinoma was explored.

Conditions

  • Endometrial Carcinoma Stage I

Interventions

DRUG

Perflubutane Microspheres for Injection

16 µL as perflubutane microbubbles (1 vial) is reconstituted with 2 mL of attached water for injection; usually, once for an adult, 0.015 mL/kg as dispersion is administered intravenously.

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Ping Liang · Chinese PLA General Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-08-01
Completion
2021-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04961775 on ClinicalTrials.gov